AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03504397
Drug: zolbetuximab
RxNorm normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
Trial: NCT03504397
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
Trial: NCT03504397
Drug: folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Trial: NCT03982862
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone 4mg diluted to 0.1 ml
Trial: NCT00743782
Drug: Synthetic Human Parathyroid Hormone 1-34
RxNorm normalized name: Parathyroid hormone (1-84) human recombinant
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04602689
Drug: Human fibrinogen concentrate
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
Trial: NCT00841971
Drug: Anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg IV loading dose followed by 100 mg qd for 21 days
Trial: NCT00841971
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg IV for 21 days
Trial: NCT03566511
Drug: Diazoxide
RxNorm normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
Trial: NCT01087242
Drug: Tang-min Lin pill
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.
Trial: NCT02723994
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
Trial: NCT02723994
Drug: Asparaginase Erwinia Chrysanthemi
RxNorm normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02741271
Drug: MF MDI 100 mcg BID (Open Label)
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
Trial: NCT02723994
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02723994
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02723994
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02723994
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02723994
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02741271
Drug: MF MDI 100 mcg BID
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
Trial: NCT02741271
Drug: Albuterol/Salbutamol PRN
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
Trial: NCT02741271
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
Trial: NCT01151787
Drug: cyclobenzaprine hydrochloride
RxNorm normalized name: Cyclobenzaprine Hydrochloride
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg daily for 3 months
Trial: NCT02723994
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03793556
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole, 2 capsules 20 mg, once a day before breakfast
Trial: NCT02570165
Drug: Batefenterol
RxNorm normalized name: Batefenterol
DrugBank: Batefenterol (DB12526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
Trial: NCT02570165
Drug: Umeclidinium/ Vilanterol
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
Trial: NCT03774979
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
Trial: NCT00668031
Drug: Trasylol (Aprotinin, BAYA0128)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
Trial: NCT03982862
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1ml 2% Xylocaine
Trial: NCT02449681
Drug: TH-4000 (Tarloxotinib)
RxNorm normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03703050
Drug: Nivolumab cohort 1
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
Trial: NCT03703050
Drug: Nivolumab cohort 2
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
Trial: NCT00001181
Drug: Testolactone
RxNorm normalized name: Testolactone
DrugBank: Testolactone (DB00894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04060862
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
Trial: NCT04060862
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
Trial: NCT04060862
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
Trial: NCT03251495
Drug: Vaxchora
RxNorm normalized name: Vaxchora
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
Trial: NCT03307512
Drug: Insulin Lispro (Humalog U-100)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Trial: NCT03982862
Drug: Botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 4U Botox® diluted to 0.1 ml
Trial: NCT01953783
Drug: IXAZOMIB
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.
Trial: NCT03031535
Drug: Intranasal octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal spray of octreotide acetate
Trial: NCT03031535
Drug: Subcutaneous octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injectable solution of octreotide acetate
Trial: NCT01789281
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
Trial: NCT01789281
Drug: Sandostatin LAR Depot
RxNorm normalized name: SandoSTATIN LAR Depot
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
Trial: NCT00289484
Drug: Omega-3 Polyunsaturated Fatty Acids
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04343729
Drug: Methylprednisolone Sodium Succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injectable solution at a dose of 0.5mg/kg
Trial: NCT01459237
Drug: Acthrel
RxNorm normalized name: Acthrel
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine Corticorelin
Trial: NCT03300960
Drug: Ganirelix (GnRH antagonist)
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
Trial: NCT00455767
Drug: EPI-hNE4
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
Trial: NCT00760214
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
Trial: NCT00760214
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
Trial: NCT00760214
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
Trial: NCT00700570
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg iv on day 1 of each 2 week cycle.
Trial: NCT00700570
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m2 iv on day 1 of each 2 week cycle
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 0.3 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 1.5 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 5.0 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 15.0 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 50 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 100 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 200 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 400 mg, Once daily, once
Trial: NCT03119064
Drug: Nanoliposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 50 mg, Once daily, once
Trial: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 800 mg, Once daily, once
Trial: NCT00150540
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02180269
Drug: JNJ-54861911 (25 mg)
RxNorm normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-54861911, 25 mg on Day 1.
Trial: NCT02180269
Drug: JNJ-54861911 (50 mg)
RxNorm normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-54861911, 50 mg on Day 1.
Trial: NCT02180269
Drug: JNJ-54861911 (100 mg)
RxNorm normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-54861911, 100 mg on Day 1.
Trial: NCT03432312
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mint lozenge, 4 mg
Trial: NCT03432312
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NiQuitin mint lozenge, 4 mg
Trial: NCT02040285
Drug: Bisacodyl & PEG-CS
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im
Trial: NCT02040285
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet
Trial: NCT02097043
Drug: DA-7218
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00736879
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Trial: NCT05032248
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral gel
Trial: NCT00931736
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
Trial: NCT00931736
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
Trial: NCT02088242
Drug: Astaxanthin
RxNorm normalized name: Astaxanthin
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
Trial: NCT00089856
Drug: Chemotherapy (Taxotere and prednisone)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Taxotere and prednisone)
Trial: NCT02943460
Drug: Cilofexor
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily with food
Trial: NCT02943460
Drug: Placebo to match cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily with food